Bausch Health Companies Inc. (NYSE:BHC – Get Free Report) saw a large drop in short interest in September. As of September 15th, there was short interest totalling 18,600,000 shares, a drop of 6.2% from the August 31st total of 19,830,000 shares. Currently, 5.8% of the company’s stock are short sold. Based on an average trading volume of 3,760,000 shares, the days-to-cover ratio is presently 4.9 days.
Insider Buying and Selling
In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $6.21, for a total value of $83,027.70. Following the sale, the executive vice president now owns 435,198 shares in the company, valued at $2,702,579.58. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 8.12% of the stock is owned by company insiders.
Institutional Investors Weigh In On Bausch Health Companies
A number of hedge funds have recently modified their holdings of the business. Salem Investment Counselors Inc. bought a new position in Bausch Health Companies in the 1st quarter worth $32,000. Headlands Technologies LLC bought a new stake in Bausch Health Companies during the 2nd quarter worth approximately $35,000. MQS Management LLC purchased a new position in Bausch Health Companies during the second quarter valued at approximately $71,000. Certuity LLC bought a new position in shares of Bausch Health Companies in the second quarter worth approximately $75,000. Finally, Bfsg LLC increased its stake in shares of Bausch Health Companies by 46.7% in the second quarter. Bfsg LLC now owns 11,450 shares of the company’s stock worth $80,000 after purchasing an additional 3,643 shares in the last quarter. Institutional investors own 78.65% of the company’s stock.
Analyst Ratings Changes
View Our Latest Report on Bausch Health Companies
Bausch Health Companies Trading Up 1.3 %
Shares of BHC stock opened at $8.27 on Wednesday. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46. The stock has a market capitalization of $2.99 billion, a P/E ratio of -6.67 and a beta of 0.75. The firm’s 50 day moving average is $6.35 and its 200 day moving average is $7.27.
Bausch Health Companies (NYSE:BHC – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.89 by $0.09. Bausch Health Companies had a negative return on equity of 742.06% and a negative net margin of 5.12%. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.33 billion. During the same quarter in the previous year, the company posted $0.81 earnings per share. As a group, equities analysts predict that Bausch Health Companies will post 3.61 earnings per share for the current year.
Bausch Health Companies Company Profile
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Read More
- Five stocks we like better than Bausch Health Companies
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 2 Energy Stocks Fueling the AI Datacenter Boom
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.